p21Waf1 is required for cellular senescence but not for cell cycle arrest induced by the HDAC inhibitor sodium butyrate

Cell Cycle

Volumn 9, Issue 19, 2010, Pages 3945-3955

  Romanov, V S ^a   Abramova, M V ^a   Svetlikova, S B ^a   Bykova, T V ^a   Zubova, S G ^a   Aksenov, N D ^a   Fornace Jr , A J ^b   Pospelova, T V ^a   Pospelov, V A ^a  

^a INSTITUTE OF CYTOLOGY   (Russian Federation)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell cycle arrest; Cell hypertrophy; HDAC inhibitors; Motility

Indexed keywords

BUTYRIC ACID; COFILIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; E1A PROTEIN; F ACTIN; HISTONE GAMMA H2AX; NUCLEAR PROTEIN; RAPAMYCIN; UNCLASSIFIED DRUG; VINCULIN;

ANIMAL CELL; ARTICLE; CELL AGING; CELL CYCLE ARREST; CELL MIGRATION; CELL TRANSFORMATION; CELLULAR PARAMETERS; DEPOLYMERIZATION; EMBRYO; FOCAL ADHESION; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; WOUND;

EID: 77958449473     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.19.13160     Document Type: Article

References (49)

1. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylase inhibitors and cancer: causes and therapies. Nature Rev Cancer 2001; 1:195-202.
2. Piekarz RL, Sackett DL, Bates SE. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Cancer J 2007; 13:30-9.
3. Bulavin DV, Tararova ND, Aksenov ND, Pospelov VA, Pospelova TV. Deregulation of p53/Rb pathway does contribute to polyploidy and apoptosis of E1A + cHa-ras transformed cells after ?irradiation. Oncogene 1999; 18:5611-9.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
5. 1/S arrest induced by HDAC inhibitor sodium butyrate in E1A + Ras transformed cells is mediated through downregulation of E2F activity and stabilization of β-catenin. J Biol Chem 2006; 281:21040-51.
6. Di Micco R, Fumagalli M, Cicalese A, Piccini S, Gasparini P, Luise C, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006; 444:638-42. (Pubitemid 44864443)
7. Bartkova J, Rezati N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444:633-7. (Pubitemid 44864442)
8. Collado M, Serrano M. The power and the promise of oncogene-induced senescence markers. Nature 2006; 6:472-6.
9. Blagosklonny MV. Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle 2006; 18:2087-102.
10. WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 2000; 19:5712-9.
11. Mallette FA, Gaumont-Leclerc MF, Ferbeyre G. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes and Dev 2007; 21:43-8.
12. Downs JA. Chromatin structure and DNA double-strand break responses in cancer progression and therapy. Oncogene 2007; 26:7765-72.
13. Ju R, Muller MT. Histone deacetylase inhibitors activate p21(WAF1) expression via ATM. Cancer Res 2003; 63:2891-7. (Pubitemid 36667161)
14. Lee J-S. Activation of ATM-dependent DNA damage signal pathway by a histone deacetylase inhibitor, trichostatin A. Cancer Res Treat 2007; 39:125-30.
15. Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of γH2AX foci. Mol Cancer Ther 2006; 5:1967-74. (Pubitemid 44336568)
16. Idogawa M, Masutani M, Shitashige M, Honda K, Tokino T, Shinomura Y, et al. Ku70 and Poly(ADP-Ribose) PolymERase-1 Competitively Regulate B-Catenin and T-Cell Factor-4-Mediated Gene Transactivation: Possible Linkage of DNA Damage Recognition and Wnt Signaling. Cancer Res 2007; 67:911-8.
17. Zhang Y, Carr T, Dimtchev A, Zaer N, Dritschilo A, Jung M. Attenuated DNA damage repair by trichostatin A through BRCA1 suppression. Radiat Res 2007; 168:115-24. (Pubitemid 351292932)
18. Nguyen TV, Puebla-Osorio N, Pang H, Dujka ME, Zhu C. DNA damage-induced cellular senescence is sufficient to suppress tumorigenesis: a mouse model. J Exp Med 2007; 204:1453-61. (Pubitemid 46919882)
19. Blagosklonny MV. Cell senescence: hypertrophic arrest beyond the restriction point. J Cell Physiol 2006; 209:592-7.
20. Pospelova TV, Demidenko ZN, Bukreeva EI, Pospelov VA, Gudkov AV, Blagosklonny MV. Pseudo-DNA damage response in senescent cells. Cell Cycle 2009; 8:4112-8.
21. Ruvinsky I, Meyuhas O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 2006; 31:342-8. (Pubitemid 43903237)
22. Blagosklonny MV. Aging-suppressants: cellular senescence (hyperactivation) and its pharmacologic deceleration. Cell Cycle 2009; 8:1883-7.
23. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV. Rapamycin decelerates cellular senescence. Cell Cycle 2009; 8:1888-95.
24. Alexandrova AY, Kopnin PB, Vasiliev JM, Kopnin BP. ROS upregulation mediates Ras-induced changes of cell morhology and motility. Exptl Cell Res 2006; 312:2066-73.
25. Jaliac S, Lopez-Rodriguez C, Shaw LN, Brown LF, Rao A, Toker A. The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nature Cell Biol 2002; 4:540-4. (Pubitemid 34752442)
26. Pollard TD, Borisy GG. Cellular motility driven by assembly and disassembly of actin filaments. Cell 2003; 113:549-59.
27. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Rev Cancer 2006; 6:38-51. (Pubitemid 43054973)
28. Schmitt CA. Cellular senescence and cancer treatment. Biochim Biophys Acta 2007; 1775:5-20.
29. WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci 2004; 101:1241-6.
30. WAf1/Cip1/Sdi1 on cellular expression: Implication for carcinogenesis, senescence and age-related diseases. Proc Natl Acad Sci 2000; 97:4291-6.
31. Hydbring P, Larsson LG. Cdk2: a key regulator of the senescence control function of Myc. Aging 2010; 4:244-50.
32. Dotto GP. p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 2000; 1471:43-56.
33. Demidenko ZN, Blagosklonny MV. Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential. Aging 2009; 1:1008-16.
34. Cuertin DA, Sabbatini DM. An expending role for mTOR in cancer. Trends Mol Med 2005; 11:252-361.
35. Haar EV, Lee SI, Bandhakavi S, Griffin TJ, Kim DH, Woo SY, et al. Insulin signalling to mTOR mediated by Akt/PKB substrate PRAS40. Nat Cell Biol 2007; 9:316-23. (Pubitemid 46344611)
36. Besson A, Assoian RK, Roberts JM. Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors? Nature Rev Cancer 2004; 4:948-55.
37. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002; 420:629-35.
38. Riedly AJ, Shwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, et al. Cell migration: integrating signals from front to back. Science 2003; 303:1704-9. (Pubitemid 37505725)
39. Cip1 is involved in Ras-induced inhibition of the ROCK/LIMK1-coffilin pathway. J Biol Chem 2004; 279:1885-91.
40. Sahai E, Olson MF, Marshall CJ. Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J 2001; 20:755-66. (Pubitemid 32167640)
41. Agnew BJ, Minamide LS, Bamburg JR. Reactivation of phosphorylated actin depolymerizing factor and identification of the regulatory site. J Biol Chem 1995; 270:17582-7.
42. DesMarais V, Ghosh M, Eddy R, Condeelis J. Cofilin takes the lead. J Cell Sci 2005; 118:19-26.
43. Are AF, Galkin VE, Pospelova TV, Pinaev GP. The p65/RelA subunit of NFkappaB interacts with actin-containing structures. Exp Cell Res 2000; 256:533-44.
44. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB. Molec Cell 2006; 22:159-68.
45. Jacinto E, Loewith R, Schmidt A, Lin S, Rüegg MA, Hall A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6:1122-8. (Pubitemid 39468014)
46. Eiseler T, Döppler H, Yan IK, Kitatani K, Mizuno K, Storz P. Protein kinase D1 regulates cofilin-mediated F-actin reorganization and cell motility through slingshot. Nat Cell Biol 2009; 11:545-56.
47. Yamaguchi H, Condeelis J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta 2007; 1773:642-52. (Pubitemid 46660177)
48. Pospelova TV, Medvedev AV, Kukushkin AN, Svetlikova SB, van der Eb AJ, Dorsman JC, et al. E1A + cHa-ras transformed rat embryo fibroblast cells are characterized by high and constitutive DNA binding activities of AP-1 dimers with significantly altered composition. Gene Expr 1999; 8:19-32.
49. Nelyudova AM, Aksenov ND, Pospelov VA, Pospelova TV. By blocking apoptosis, Bcl-2 in p38-dependent manner promotes cell cycle arrest and accelerated senescence after DNA damage and serum withdrawal. Cell Cycle 2007; 6:2171-7.